<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Monoclonal antibodies have provided new promise for patients with B-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Rituximab is a monoclonal antibody against B-lymphocytes that express CD20; it is used for the treatment of patients with relapsed or refractory B-cell non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Very few data are available regarding the treatment of children with non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> with rituximab </plain></SENT>
<SENT sid="3" pm="."><plain>In this article, we reported three children with primary refractory/relapsed B-cell-non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, who were successfully treated with a combination of intensive chemotherapy protocol plus rituximab </plain></SENT>
<SENT sid="4" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo> three of our cases, the patients are still in complete remission </plain></SENT>
<SENT sid="5" pm="."><plain>Our aim is to emphasize the importance of use of rituximab in the treatment of childhood B-cell non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
</text></document>